Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.
What Sun files
- Others51
- Important12
- Updates11
- Board Meeting10
- PPTs4
- Results2
SPARC received requests from shareholders holding 0.5979 Cr shares (1.85%) to reclassify from 'Promoter Group' to 'Public' category. The Board will consider this reclassification in due course.
SPARC will hold its 21st Annual General Meeting virtually to review the FY25-26 Annual Report. A cut-off date is set for voting eligibility. Shareholders are advised to update contact details for timely report access.
SPARC received ~₹1500 Cr from Shanghvi Finance for a preferential allotment of 3.85 Cr warrants. This significant capital infusion boosts SPARC's financial strength, paving the way for future strategic advancements.
SPARC is consolidating R&D labs to two Baroda sites from multiple locations. This strategic move targets enhanced operational efficiency, reduced costs, and faster pipeline development. Outsourcing some R&D, with capacity adjustments underway. No impact on current pipeline.
SPARC has shifted strategic focus to oncology and immunology. Key R&D assets advanced: SCD-153 (Alopecia Areata) entered Phase 1b, while SBO-154 (cancer ADC) received a "study may proceed" from USFDA, with an IND also filed in India. Setbacks include pausing Vodobatinib’s Parkinson's development and Vibozilimod studies missing primary endpoints. Consolidated...